Cargando…

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma

BACKGROUND: Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor survival. This study reports the associations between renal function and disease characteristics including serum free light chain (FLC) level at diagnosis in patients with MM. METHODS: Using data from th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yadav, Punit, Cockwell, Paul, Cook, Mark, Pinney, Jennifer, Giles, Hannah, Aung, Yu Sandar, Cairns, David, Owen, Roger G., Davies, Faith E., Jackson, Graham H., Child, J. Anthony, Morgan, Gareth J., Drayson, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048743/ https://www.ncbi.nlm.nih.gov/pubmed/30012107 http://dx.doi.org/10.1186/s12882-018-0962-x

Ejemplares similares

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test
por: Heaney, Jennifer L. J., et al.
Publicado: (2017)

Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study
por: Yadav, Punit, et al.
Publicado: (2020)

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report
por: Rana, Ritika, et al.
Publicado: (2018)

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
por: Hutchison, Colin A, et al.
Publicado: (2012)

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
por: Boyle, Eileen M, et al.
Publicado: (2015)

Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
por: Croft, James, et al.
Publicado: (2020)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report
por: Rana, Ritika, et al.
Publicado: (2021)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report
por: Basnayake, Kolitha, et al.
Publicado: (2008)

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
por: Khanim, F L, et al.
Publicado: (2011)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
por: Boyd, Kevin D, et al.
Publicado: (2011)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease
por: Fenton, Anthony, et al.
Publicado: (2018)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
por: Weinhold, Niels, et al.
Publicado: (2021)

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2015)

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment
por: Fryer, Rosemary A., et al.
Publicado: (2013)

Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease
por: Lodi, Alessia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q4lfa13j048s7n4f9m69mn54br